Angiogenic inhibition in high-grade gliomas: Past, present and future

Expert Review of Neurotherapeutics

Volumn 12, Issue 6, 2012, Pages 733-747

  Jo, Jasmin ^a   Schiff, David ^a   Purow, Benjamin ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

angiogenesis; bevacizumab; biomarkers; glioma stem cells; high grade glioma; VEGF; VEGFR tyrosine kinase inhibitors

Indexed keywords

AMGEN 386; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BEVACIZUMAB; BUPARLISIB; CILENGITIDE; ENZASTAURIN; ERLOTINIB; ETOPOSIDE; IRINOTECAN; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NINTEDANIB; PEGDINETANIB; RILOTUMUMAB; RO 5323441; SORAFENIB; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER DIAGNOSIS; CANCER SURVIVAL; DRUG MECHANISM; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; NEUROIMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; FORECASTING; GLIOBLASTOMA; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84861744127     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.53     Document Type: Review

References (151)

1. CBRTUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Central Brain Tumor Registry of the United States (CBRTUS), Hinsdale, IL, USA (2011
2. Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups. National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuVant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005 (Pubitemid 40349501)
3. Stupp R, Hegi ME, Mason WP et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups. National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuVant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009
4. Prados MD, Gutin PH, Phillips TL et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int. J. Radiat. Oncol. Biol. Phys. 23(1), 3-8 (1992
5. Prados MD, Seiferheld W, Sandler HM et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int. J. Radiat. Oncol. Biol. Phys. 58(4), 1147-1152 (2004 (Pubitemid 38314798)
6. Van de Bent MJ, Carpentier AF, Brandes AA et al. AdjuVant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol. 24, 2715-2722 (2006 (Pubitemid 46630567)
7. Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83(5), 588-593 (2000 (Pubitemid 30636298)
8. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17(9), 2762-2771 (1999 (Pubitemid 29415233)
9. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009
10. Avastin®, package insert. Genentech USA, Inc, CA, USA (2011
11. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009
12. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438(7070), 932-936 (2005 (Pubitemid 43093958)
13. Risau W, Flamme I. Vasculogenesis. Annu. Rev. Cell Dev. Biol. 11, 73-91 (1995 (Pubitemid 26019602)
14. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000
15. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann. Surg. 164(3), 491-502 (1966
16. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82(1), 4-6 (1990 (Pubitemid 20020880)
17. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971
18. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284(5422), 1994-1998 (1999 (Pubitemid 29309448)
19. Leenders WP, Kusters B, de Waal RM. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 9(2), 83-87 (2002 (Pubitemid 35252016)
20. Zagzag D, Amirnovin R, Greco MA et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab. Invest. 80(6), 837-849 (2000 (Pubitemid 30421801)
21. Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J. Neurooncol. 78(3), 281-293 (2006 (Pubitemid 44018823)
22. Folkman J. Angiogenesis: initiation and control. Ann. N. Y. Acad. Sci. 401, 212-227 (1982 (Pubitemid 13088402)
23. Folkman J. Tumor angiogenesis. Adv. Cancer Res. 43, 175-203 (1985
24. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 46(2), 467-473 (1986 (Pubitemid 16145386)
25. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67(6), 2729-2735 (2007 (Pubitemid 46548961)
26. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61(16), 6020-6024 (2001 (Pubitemid 32762531)
27. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003 (Pubitemid 36749215)
28. Herold-Mende C, Steiner HH, Andl T et al. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab. Invest. 79(12), 1573-1582 (1999 (Pubitemid 30013922)
29. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J. Biol. Chem. 275(22), 16986-16992 (2000 (Pubitemid 30398939)
30. Ellis LM. The role of neuropilins in cancer. Mol. Cancer Ther. 5, 1099-1107 (2006 (Pubitemid 43881301)
31. Takano S, Yoshii Y, Kondo S et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56(9), 2185-2190 (1996 (Pubitemid 26119923)
32. Schmidt N, Westphal M, Hagel C. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer 84, 10-18 (1999 (Pubitemid 29059101)
33. Ding H, Roncari L, Wu X et al. Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro-oncology 3(1), 1-10 (2001 (Pubitemid 33685580)
34. Samoto K, Ikezaki K, Ono M et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res. 55(5), 1189-1193 (1995
35. Peters BA, Diaz LA, Polyak K et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 11(3), 261-262 (2005 (Pubitemid 40460552)
36. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ. Res. 86(1), 24-29 (2000 (Pubitemid 30044164)
37. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322), 55-60 (1997 (Pubitemid 27450643)
38. Yoshiji H, Kuriyama S, Yoshii J et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35(4), 834-842 (2002 (Pubitemid 34258377)
39. Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell. Sci. 110(Pt 18), 2293-2302 (1997 (Pubitemid 27448373)
40. Guo P, Hu B, Gu W et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162(4), 1083-1093 (2003 (Pubitemid 36350654)
41. Wang D, Huang HJ, Kazlauskas A, Cavenee WK. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 59(7), 1464-1472 (1999 (Pubitemid 29160112)
42. Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J. Neurooncol. 50(1-2), 121-137 (2000 (Pubitemid 32169649)
43. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett. 102(1-2), 209-215 (1996 (Pubitemid 26097822)
44. Platten M, Wick W, Weller M. High-grade glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc. Res. Tech. 52(4), 401-410 (2001
45. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. Biochem. Biophys. Res. Commun. 268(2), 607-611 (2000 (Pubitemid 30119669)
46. Kunkel P, Müller S, Schirmacher P et al. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro-oncology 3(2), 82-88 (2001 (Pubitemid 33691765)
47. Loeffler S, Fayard B, Weis J, Weissenberger J. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int. J. Cancer 115(2), 202-213 (2005 (Pubitemid 40586728)
48. Wakabayashi Y, Shono T, Isono M et al. Dual pathways of tubular morphogenesis of vascular endothelial cells by human glioma cells: vascular endothelial growth factor/ basic fibroblast growth factor and interleukin-8. Jpn. J. Cancer Res. 86(12), 1189-1197 (1995
49. Rolhion C, Penault-Llorca F, Kémény JL et al. Interleukin-6 overexpression as a marker of malignancy in human gliomas. J. Neurosurg. 94(1), 97-101 (2001 (Pubitemid 32799478)
50. Maruno M, Kovach JS, Kelly PJ, Yanagihara T. Distribution of endogenous tumour necrosis factor alpha in gliomas. J. Clin. Pathol. 50(7), 559-562 (1997 (Pubitemid 27359511)
51. Roessler K, Suchanek G, Breitschopf H et al. Detection of tumor necrosis factor-alpha protein and messenger RNA in human glial brain tumors: comparison of immunohistochemistry with in situ hybridization using molecular probes. J. Neurosurg. 83(2), 291-297 (1995
52. Chambaut-Guérin AM, Costa SL, Lefrançois T, Fages C, Gauthereau X, Tardy M. Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells. Neuroreport 11(2), 389-393 (2000 (Pubitemid 30074655)
53. Yoshida S, Ono M, Shono T et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell. Biol. 17(7), 4015-4023 (1997 (Pubitemid 27281877)
54. Bello L, Francolini M, Marthyn P et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49(2), 380-389; discussion 390 (2001
55. D'Abaco GM, Kaye AH. Integrins: molecular determinants of glioma invasion. J. Clin. Neurosci. 14(11), 1041-1048 (2007 (Pubitemid 47588943)
56. Binder DK, Berger MS. Proteases and the biology of glioma invasion. J. Neurooncol. 56(2), 149-158 (2002 (Pubitemid 34272306)
57. Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64(19), 7011-7021 (2004 (Pubitemid 39331011)
58. Hemmati HD, Nakano I, Lazareff JA et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 100(25), 15178-15183 (2003 (Pubitemid 37518036)
59. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821-5828 (2003 (Pubitemid 37187480)
60. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 432(7015), 396-401 (2004 (Pubitemid 39551674)
61. Bao S, Wu Q, McLendon RE et al. Stem cell-like glioma cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006 (Pubitemid 44949604)
62. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11(1), 69-82 (2007 (Pubitemid 46054518)
63. Folkins C, Shaked Y, Man S et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res. 69(18), 7243-7251 (2009
64. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem. Pharmacol. 80(5), 654-665 (2010
65. Lathia JD, Hitomi M, Gallagher J et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis. 2, e200 (2011
66. Garcia JL, Perez-Caro M, Gomez-Moreta JA et al. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas. BMC Cancer 10, 454 (2010
67. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312(5777), 1171-1175 (2006 (Pubitemid 43801134)
68. Sathornsumetee S, Rich JN. Antiangiogenic therapy in high-grade glioma: promise and challenge. Curr. Pharm. Des. 13(35), 3545-3558 (2007 (Pubitemid 350238925)
69. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005 (Pubitemid 40093472)
70. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006 (Pubitemid 43108832)
71. Gorski DH, Beckett MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59(14), 3374-3378 (1999 (Pubitemid 29334495)
72. Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. 67(15), 7055-7058 (2007 (Pubitemid 47206528)
73. Browder T, Butterfield CE, Kräling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60(7), 1878-1886 (2000 (Pubitemid 30207647)
74. Bertolini F, Paul S, Mancuso P et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63(15), 4342-4346 (2003 (Pubitemid 36951001)
75. Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66(16), 7843-7848 (2006 (Pubitemid 44299144)
76. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3(5), 391-400 (2004 (Pubitemid 38618122)
77. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004 (Pubitemid 38702844)
78. Stark Vance V. Bevacizumab and CPT-11 in the treatment of relapsed high-grade glioma. Neuro-Oncology 7, Abstract 342 (2005
79. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8), 1258-1260 (2006 (Pubitemid 43739717)
80. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent high-grade glioma. Clin. Cancer Res. 13(4), 1253-1259 (2007 (Pubitemid 46424067)
81. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial high-grade glioma. J. Clin. Oncol. 8(7), 1277-1280 (1990 (Pubitemid 20195640)
82. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007 (Pubitemid 350086473)
83. Desjardins A, Vredenburgh JJ, Reardon DA et al. Long-term survival from the initial trial of bevacizumab and irinotecan. J. Clin. Oncol. 28(Suppl. 15), Abstract 2045 (2010
84. Vredenburgh JJ, Cloughesy T, Samant M et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12), 1329-1334 (2010
85. Wefel JS, Cloughesy T, Zazzali JL et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-oncology 13(6), 660-668 (2011
86. Taillibert S, Vincent LA, Granger B et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 72(18), 1601-1606 (2009
87. Reardon DA, Desjardins A, Vredenburgh JJ et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent high-grade glioma: a Phase II study. Br. J. Cancer 101(12), 1986-1994 (2009
88. Chinot OL, de La Motte Rouge T, Moore N et al. Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme (ND-GBM) [abstract]. Neuro. Oncol. 11(5), 628 (2009
89. Desjardins A, Reardon DA, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 high-grade gliomas. Clin. Cancer Res. 14(21), 7068-7073 (2008
90. Kreisl TN, Zhang W, Odia Y et al. A Phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-oncology 13(10), 1143-1150 (2011
91. Francesconi AB, Dupre S, Matos M et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J. Clin. Neurosci. 17(8), 970-974 (2010
92. Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J. Neurooncol. 89(1), 113-118 (2008
93. Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91(3), 329-336 (2009
94. Ali SA, McHayleh WM, Ahmad A et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J. Neurosurg. 109(2), 268-272 (2008
95. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112(10), 2267-2273 (2008 (Pubitemid 351628638)
96. Hasselbalch B, Lassen U, Hansen S et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a Phase II trial. Neuro-oncology 12(5), 508-516 (2010
97. Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72(14), 1217-1222 (2009
98. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent high-grade gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10), 779-787 (2008
99. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent high-grade glioma. Neuro-oncology 12(12), 1300-1310 (2010
100. Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofrationated stereotactic irradiation for recurrent high-grade gliomas. Int. J. Radiar. Oncol. Biol. Phys. 75(1), 156-163 (2009
101. Mathieu V, De Nève N, Le Mercier M et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10(12), 1383-1392 (2008
102. Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99(17), 11393-11398 (2002 (Pubitemid 34920936)
103. Gomez-Manzano C, Holash J, Fueyo J et al. VEGF Trap induces antiglioma effect at different stages of disease. Neurooncology 10(6), 940-945 (2008
104. De Groot JF, Lamborn KR, Chang SM et al. Phase II study of aflibercept in recurrent high-grade glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 29(19), 2689-2695 (2011
105. Wachsberger PR, Burd R, Cardi C et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 67(5), 1526-1537 (2007 (Pubitemid 46467151)
106. Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for high-grade glioma. Curr. Treat. Options Oncol. 9(1), 1-22 (2008
107. Brandsma D, Van den Bent MJ. Molecular targeted therapies and chemotherapy in high-grade gliomas. Curr. Opin. Oncol. 19(6), 598-605 (2007
108. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83-95 (2007 (Pubitemid 46075199)
109. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010
110. Batchelor T, Mulholland P, Neyns B. The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a Phase III randomized study. Neuro-Oncology, 12(Suppl. 4), iv69-iv78 (2010
111. Neyns B, Sadones J, Chaskis C et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J. Neurooncol. 103(3), 491-501 (2011
112. Iwamoto FM, Lamborn KR, Robins HI et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-oncology 12(8), 855-861 (2010
113. De Groot JF, Prados M, Urquhart, T et al. A Phase II study of XL184 in patients with progressive glioblastoma multiforme (GBM) in first or second relapse. J. Clin. Oncol. 27(Suppl. 15), Abstract 2047 (2009
114. Lacouture M, Lenihan D, Quaggin S. Targeting Tumor Angiogenesis. Antiangiogenic therapy: tolerability and management of side effects. The Angiogenesis Foundation (2009
115. Armstrong TS, Wen PY, Gilbert MR, Schiff D et al. Management of treatment associated toxicities of anti-anigogenic therapy in patients with brain tumors. Neuro-Oncol doi:10.1093/neuonc/nor223 (2012) (Epub ahead of print
116. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96(12), 1788-1795 (2007 (Pubitemid 46912024)
117. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49(2), 186-193 (2007 (Pubitemid 46178407)
118. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358(11), 1129-1136 (2008 (Pubitemid 351398487)
119. Levy CF, Oo KZ, Fireman F et al. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr. Blood Cancer 52(5), 669-671 (2009
120. Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 91(3), 173-180 (2005 (Pubitemid 41254420)
121. Shen Q, Goderie SK, Jin L et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 304(5675), 1338-1340 (2004 (Pubitemid 38697433)
122. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J. Biol. 5(7), 22 (2006
123. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592-603 (2008
124. Du R, Lu KV, Petritsch C et al. HIF1alpha induces the recruitment of bone marrowderived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13(3), 206-220 (2008 (Pubitemid 351318372)
125. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat. Rev. Neurol. 5(11), 610-620 (2009
126. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl Acad. Sci. USA 104(43), 17069-17074 (2007 (Pubitemid 350210993)
127. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18(2), 338-340 (2004
128. Motzer R, Escudier B, Oudard S et al.; RECORD-1 Study Group. Efficacy of everolimus in adVanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008
129. Jaeckle KA, Schiff D, Anderson SK et al. NCCTG N0572 Phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: a North Central Cancer Treatment Group study. J. Clin. Oncol. 29(Suppl.), Abstract 2033 (2011
130. Blouw B, Song H, Tihan T et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4(2), 133-146 (2003 (Pubitemid 37040829)
131. Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for high-grade glioma: treatment effects and escape mechanisms. Expert Opin. Ther. Targets 13(4), 455-468 (2009
132. Keunen O, Johansson M, Oudin A et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. USA 108(9), 3749-3754 (2011
133. Iwamoto FM, Abrey LE, Beal K et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73(15), 1200-1206 (2009
134. Fischer I, Cunliffe CH, Bollo RJ et al. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro-oncology 10(5), 700-708 (2008
135. Wick A, Dörner N, Schäfer N et al. Bevacizumab does not increase the risk of remote relapse in high-grade glioma. Ann. Neurol. 69(3), 586-592 (2011
136. Pope WB, Xia Q, Paton VE et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 76(5), 432-437 (2011
137. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28(11), 1963-1972 (2010
138. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J. Clin. Oncol. 24(20), 3293-3298 (2006 (Pubitemid 46622069)
139. Sorensen AG, Batchelor TT, Zhang W-T et al. A 'vascular normalization index' as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296-5300 (2009
140. Jain R, Scarpace LM, Ellika S et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J. Neurooncol. 96(3), 423-431 (2010
141. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro-oncology 12(5), 466-472 (2010
142. Essock-Burns E, Lupo JM, Cha S et al. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro-oncology 13(1), 119-131 (2011
143. Chen W, Delaloye S, Silverman DH et al. Predicting treatment response of highgrade gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25(30), 4714-4721 (2007 (Pubitemid 350086472)
144. Prados M, Cloughesy T, Samant M et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-oncology 13(1), 143-151 (2011
145. Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26(2), 271-278 (2008
146. Hasselbalch B, Eriksen JG, Broholm H et al. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 118(8), 585-594 (2010
147. De Groot JF, Piao Y, Tran H et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin. Cancer Res. 17(14), 4872-4881 (2011
148. Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J. Neurooncol. 105(2), 325-335 (2011
149. Pallini R, Ricci-Vitiani L, Montano N et al. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer 117(1), 162-174 (2011
150. Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro-oncology 11(3), 301-310 (2009
151. De Groot JF. High-dose antiangiogenic therapy for glioblastoma: less may be more? Clin. Cancer Res. 17(19), 6109-6111 (2011)